Evidence map›Paper›PMID 38001571›Full record

ArticleCancers2023

MicroRNA Profiling of Red Blood Cells for Lung Cancer Diagnosis.

Xinyan Geng, Jie Ma, Pushpa Dhilipkannah, Feng Jiang

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Xinyan GengDepartments of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Jie MaDepartments of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Pushpa DhilipkannahDepartments of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Feng JiangDepartments of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0001-8510-3049
University of Maryland, Baltimore · US

Funding

Plasma microRNA biomarkers for lung cancer diagnosisUH3CA251139 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Feng Jiang · 2023 to 2026
$882k
Plasma biomarkers for lung cancer diagnosisUH2CA251139 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI JIANG, FENG · 2020 to 2021
$370k
NCI NIH HHS CA251139-03NCI NIH HHS UH3 CA251139
6 · The paper itself

Abstract

backgroundDespite extensive endeavors to establish cell-free circulating biomarkers for lung cancer diagnosis, clinical adoption remains elusive. Noteworthy, emergent evidence suggests the pivotal roles of red blood cells (RBCs) and their derivatives in tumorigenesis, illuminating potential avenues for diagnostic advancements using blood cell-derived microRNAs (miRNAs).

methodsWe executed microarray analyses on three principal blood cell types-RBCs, peripheral blood mononuclear cells (PBMCs), and neutrophils-encompassing 26 lung cancer patients and 26 healthy controls. Validation was performed using droplet digital PCR within an additional cohort comprising 42 lung cancer and 39 control cases.

resultsOur investigation unearthed distinct miRNA profiles associated with lung cancer across all examined blood cell types. Intriguingly, RBC-miRNAs emerged as potential novel biomarkers for lung cancer, an observation yet to be documented. Importantly, integrating miRNAs from disparate blood cell types yielded a superior diagnostic accuracy for lung cancer over individual cell-type miRNAs. Subsequently, we formulated three diagnostic panels, adeptly discerning non-small cell lung cancer, adenocarcinoma, and squamous cell carcinoma, maintaining consistency across various disease stages.

conclusionRBC-derived molecules introduce novel cancer biomarkers, and exploiting miRNA profiles across varied blood cell types unveils a promising frontier for lung cancer's early detection and histological classification.

Indexed as

biomarkersdiagnosislung cancermiRNAsred blood cells

Identifiers

PMID38001571
PMCPMC10670279
OpenAlexW4388453209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.